Heineken warns: weight-loss products threaten beer sales

The rise of weight-loss drugs such as Ozempic and Wegovy is having a growing impact on the beer industry. Heineken warns British bar and restaurant owners that consumers drink less alcohol and urge them to adjust their offerings. Research confirms that these drugs can significantly reduce alcohol consumption.

Fewer pints

In an internal presentation to British hospitality business owners—which the Reuters news agency was able to review—Heineken acknowledges that the popularity of weight-loss drugs poses a risk to beer sales. Drugs from the so-called GLP-1 family not only reduce appetite but can also curb the desire for alcohol. Furthermore, users feel full more quickly, causing them to drink smaller amounts.